{"created":"2023-06-19T10:40:37.819661+00:00","id":149,"links":{},"metadata":{"_buckets":{"deposit":"0b0af6a1-e79d-45af-af31-18f905db091d"},"_deposit":{"created_by":3,"id":"149","owners":[3],"pid":{"revision_id":0,"type":"depid","value":"149"},"status":"published"},"_oai":{"id":"oai:shiga-med.repo.nii.ac.jp:00000149","sets":["6:7:125:126"]},"author_link":["491","494","454","492","456","302","489","490","137","165","495"],"item_3_alternative_title_18":{"attribute_name":"その他の言語のタイトル","attribute_value_mlt":[{"subitem_alternative_title":"Results of IMRT following neoadjuvant hormone therapy for clinical stage C prostate cancer"}]},"item_3_alternative_title_19":{"attribute_name":"タイトル（ヨミ）","attribute_value_mlt":[{"subitem_alternative_title":"Stage C ゼンリツセンガン ニ タイスル ナイブンピツ ホルモン リョウホウ ヘイヨウ キョウド ヘンチョウ ホウシャセン チリョウ IMRT ノ チュウキ チリョウ セイセキ"}]},"item_3_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2012-11-07","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"12","bibliographicPageStart":"6","bibliographicVolumeNumber":"26","bibliographic_titles":[{"bibliographic_title":"滋賀医科大学雑誌"}]}]},"item_3_description_42":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"subitem_description":"Departmental Bulletin Paper","subitem_description_type":"Other"}]},"item_3_description_5":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"We report the 5-year prostate-specific antigen (PSA) relapse-free survival outcome and incidence of toxicity forpatients with clinically Stage C prostate cancer treated with intensity-modulated radiation therapy (IMRT) in our institute. Atotal of 35 patients with Stage C prostate cancer were treated with IMRT between July 2003 and November 2007. All patientswere treated to a dose of 74Gy prescribed to the planning target volume and received neoadjuvant hormone therapy. Themedian age was 71 years (range: 50 to 80 years). 3 patients (8.6%) had Gleason scores ＜or=6, 14 patients (40.0%) hadGleason scores 7, 18 patients (51.4%) had Gleason scores >or=8. The median pretreatment PSA level was 28.0 ng/mL (range:5.1 to 160.0 ng/mL). Patients were characterized as having high risk disease if their pretreatment PSA level was >20ng/ml andGleason score >or=8. PSA relapse-free survival rate were calculated and toxicity data were scored according to the CommonTerminology Criteria for Adverse Events Version 3.0. The median follow-up time was 58 months (range 7 to 84). 11 patients(31.4%) developed a PSA relapse, and the 5-year PSA relapse-free survival rate was 66.3%. The 5-year PSA relapse-freesurvival rates for high risk patients and others were 39.2% and 85.7%, respectively (p=0.0098). The likelihood of acute grade 2urinary and rectal toxicity was 14.2% and 11.4%. No grade 2 late complications have been observed. These results indicatedthat 74Gy IMRT is well tolerated and is associated with good PSA relapse-free survival outcomes in patients with Stage Cprostate cancer, especially non-high risk patient.","subitem_description_type":"Other"}]},"item_3_publisher_32":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"滋賀医科大学雑誌編集委員会"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"河野, 直明"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"邵, 啓全"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"津川, 拓也"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"村田, 喜代史"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"野間, 和夫"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"本多, 恵理子"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"橋本, 惠次"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"近藤, 康雄"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Ushida, Hiroshi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"岡本, 圭生"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"岡田, 裕作"}],"nameIdentifiers":[{},{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2017-02-16"}],"displaytype":"detail","filename":"jsums2601p006.pdf","filesize":[{"value":"476.8 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"jsums2601p006.pdf","url":"https://shiga-med.repo.nii.ac.jp/record/149/files/jsums2601p006.pdf"},"version_id":"ff743b7a-561b-46cd-ac70-f1385ddbe821"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Stage C 前立腺癌に対する内分泌ホルモン療法併用強度変調放射線治療（IMRT）の中期治療成績","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Stage C 前立腺癌に対する内分泌ホルモン療法併用強度変調放射線治療（IMRT）の中期治療成績"}]},"item_type_id":"3","owner":"3","path":["126"],"pubdate":{"attribute_name":"公開日","attribute_value":"2016-04-12"},"publish_date":"2016-04-12","publish_status":"0","recid":"149","relation_version_is_last":true,"title":["Stage C 前立腺癌に対する内分泌ホルモン療法併用強度変調放射線治療（IMRT）の中期治療成績"],"weko_creator_id":"3","weko_shared_id":3},"updated":"2023-06-19T11:34:38.029267+00:00"}